TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,537,162 | -26.2% | 171,942 | +26.9% | 0.00% | 0.0% |
| Q2 2023 | $2,081,863 | -26.1% | 135,538 | +8.2% | 0.00% | 0.0% |
| Q1 2023 | $2,816,468 | +77.9% | 125,232 | +66.3% | 0.00% | 0.0% |
| Q4 2022 | $1,583,412 | +0.3% | 75,293 | +17.5% | 0.00% | 0.0% |
| Q3 2022 | $1,579,000 | +188.1% | 64,082 | +183.5% | 0.00% | – |
| Q2 2022 | $548,000 | -1.8% | 22,601 | +4.4% | 0.00% | – |
| Q1 2022 | $558,000 | -15.8% | 21,644 | +1.4% | 0.00% | – |
| Q4 2021 | $663,000 | +28.7% | 21,346 | +0.5% | 0.00% | – |
| Q3 2021 | $515,000 | +238.8% | 21,238 | +103.8% | 0.00% | – |
| Q2 2021 | $152,000 | -47.6% | 10,422 | -10.3% | 0.00% | – |
| Q1 2021 | $290,000 | +7.4% | 11,613 | +17.4% | 0.00% | – |
| Q4 2020 | $270,000 | – | 9,895 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |